Pharmaceutical composition, methods for treating and uses thereof
AssigneeBoehringer Ingelheim International GmbH
InventorsUli Christian BROEDL, Maximilian von EYNATTEN, Odd-Erik JOHANSEN, Thomas KLEIN, Gerd Roland LUIPPOLD
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment or prevention of renal impairment and/or complications using a SGLT-2 inhibitor, for example in patients diagnosed with metabolic disorders and related conditions.
Claims14
A method for preventing, slowing the progression of, delaying or treating renal hyperfiltrative injury in a patient in need thereof characterized in that a pharmaceutical composition comprising 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, or a prodrug thereof, is administered to the patient in a range from about 10 mg to 25 mg, wherein the patient has a glomerular filtration rate (GFR) equal to or greater than 125 mL/min/1.73 m2.
A method for preventing, slowing the progression of, delaying or treating a condition or disorder selected from the group consisting of hyperfiltrative diabetic nephropathy, renal hyperfiltration, glomerular hyperfiltration, renal allograft hyperfiltration, compensatory hyperfiltration (e.g. after renal mass reduction by surgery), hyperfiltrative chronic kidney disease, hyperfiltrative acute renal failure, compensatory hyperfiltration in association with obstructive uro/nephropathy and morbid obesity in a patient in need thereof characterized in that a pharmaceutical composition comprising 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene or a prodrug thereof, is administered to the patient in a range from about 10 mg to 25 mg, wherein the patient has a glomerular filtration rate (GFR) equal to or greater than 125 mL/min/1.73 m2.
Dependencies are inferred from the claim text.